AU2019312565B2 - Anti-MICA/B antibodies that block MICA/B shedding and methods of use - Google Patents

Anti-MICA/B antibodies that block MICA/B shedding and methods of use

Info

Publication number
AU2019312565B2
AU2019312565B2 AU2019312565A AU2019312565A AU2019312565B2 AU 2019312565 B2 AU2019312565 B2 AU 2019312565B2 AU 2019312565 A AU2019312565 A AU 2019312565A AU 2019312565 A AU2019312565 A AU 2019312565A AU 2019312565 B2 AU2019312565 B2 AU 2019312565B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
set forth
mica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019312565A
Other languages
English (en)
Other versions
AU2019312565A1 (en
Inventor
Justin Chapman
Xin Du
Neil Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cullinan Mica Corp
Original Assignee
Cullinan Mica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Mica Corp filed Critical Cullinan Mica Corp
Publication of AU2019312565A1 publication Critical patent/AU2019312565A1/en
Application granted granted Critical
Publication of AU2019312565B2 publication Critical patent/AU2019312565B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019312565A 2018-07-31 2019-07-30 Anti-MICA/B antibodies that block MICA/B shedding and methods of use Active AU2019312565B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712608P 2018-07-31 2018-07-31
US62/712,608 2018-07-31
PCT/US2019/044234 WO2020028428A2 (en) 2018-07-31 2019-07-30 Anti-mica/b antibodies that block mica/b shedding and methods of use

Publications (2)

Publication Number Publication Date
AU2019312565A1 AU2019312565A1 (en) 2021-03-11
AU2019312565B2 true AU2019312565B2 (en) 2025-09-11

Family

ID=69231308

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019312565A Active AU2019312565B2 (en) 2018-07-31 2019-07-30 Anti-MICA/B antibodies that block MICA/B shedding and methods of use

Country Status (14)

Country Link
US (2) US12065493B2 (https=)
EP (1) EP3830128A4 (https=)
JP (2) JP7370376B2 (https=)
KR (1) KR102832008B1 (https=)
CN (2) CN119930819A (https=)
AU (1) AU2019312565B2 (https=)
CA (1) CA3108022A1 (https=)
IL (1) IL280487B2 (https=)
MX (1) MX2021001254A (https=)
MY (1) MY207765A (https=)
PH (1) PH12021550232A1 (https=)
SG (1) SG11202100981TA (https=)
WO (1) WO2020028428A2 (https=)
ZA (1) ZA202101258B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN115611982B (zh) * 2021-07-14 2024-05-10 浙江大学 一种抗人MICA/Bα3区的单克隆抗体及其应用
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
US20250340651A1 (en) * 2022-07-28 2025-11-06 Cullinan Mica Corporation Anti-mica/b antibodies with enhanced effector function and methods of use
CN118027195B (zh) 2023-05-06 2025-07-04 合肥天港免疫药物有限公司 亲和力成熟的mica抗体及其应用
CN119569886A (zh) 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2025085672A1 (en) * 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013117647A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
WO2018081648A2 (en) * 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483343A1 (en) 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
EP2289534B1 (en) 2004-04-05 2017-08-30 The Regents of The University of California NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
EP1857116A1 (en) 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
CA3011859A1 (en) 2007-04-23 2008-10-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
HUE034044T2 (en) 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
US20150044224A1 (en) 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
EP2970490A4 (en) 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2014190914A1 (en) 2013-05-30 2014-12-04 The University Of Hong Kong Materials and methods for treatment of liver cancer background of the invention
AU2015264114A1 (en) 2014-05-21 2016-11-03 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti BiP or anti MICA antibodies
EP3430047A1 (en) * 2016-03-15 2019-01-23 Innate Pharma Anti-mica antibodies
WO2017209318A1 (ko) * 2016-05-30 2017-12-07 다이노나(주) 탄산탈수소화 효소에 결합하는 항체 및 이의 용도
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
EP3293271A1 (en) 2016-09-12 2018-03-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Marker and target as a diagnostic variable and target for therapy of metastatic cancer
CA3040421A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
EP3577138A1 (en) 2017-02-06 2019-12-11 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN112566659A (zh) 2018-01-25 2021-03-26 库利南Mica公司 Mica/b抗体和使用方法
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
EP3773676A4 (en) 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013117647A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
WO2018081648A2 (en) * 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Whalen KA et al. CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity. J Immunother Cancer. 2025 Apr 23;13(4):e008987. doi: 10.1136/jitc-2024-008987. PMID: 40274283; PMCID: PMC12020772 *

Also Published As

Publication number Publication date
MY207765A (en) 2025-03-17
US20210253711A1 (en) 2021-08-19
AU2019312565A1 (en) 2021-03-11
JP2021532774A (ja) 2021-12-02
US20250034262A1 (en) 2025-01-30
WO2020028428A3 (en) 2020-05-07
SG11202100981TA (en) 2021-02-25
MX2021001254A (es) 2021-05-12
CN113056484A (zh) 2021-06-29
CA3108022A1 (en) 2020-02-06
US12065493B2 (en) 2024-08-20
CN113056484B (zh) 2025-01-14
IL280487B2 (en) 2025-07-01
BR112021001808A2 (pt) 2021-08-03
JP7370376B2 (ja) 2023-10-27
PH12021550232A1 (en) 2021-12-06
IL280487B1 (en) 2025-03-01
CN119930819A (zh) 2025-05-06
KR20210071947A (ko) 2021-06-16
EP3830128A2 (en) 2021-06-09
EP3830128A4 (en) 2022-08-17
IL280487A (en) 2021-03-25
WO2020028428A2 (en) 2020-02-06
JP2024009997A (ja) 2024-01-23
JP7734720B2 (ja) 2025-09-05
ZA202101258B (en) 2025-06-25
KR102832008B1 (ko) 2025-07-10

Similar Documents

Publication Publication Date Title
AU2019312565B2 (en) Anti-MICA/B antibodies that block MICA/B shedding and methods of use
US20240092902A1 (en) Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
AU2019211411B2 (en) MICA/B antibodies and methods of use
CN108601829B (zh) 抗pd-1抗体及其治疗用途
EP3604338A1 (en) Anti-ox40 antibody and use thereof
HK1254289A1 (zh) 调控免疫反应的方法及抗体
EA031069B1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
JP2023531042A (ja) ４－１ｂｂ結合タンパク質及びその用途
KR20230019468A (ko) 비고전적 hla-i 및 신생항원을 포함하는 복합체를 표적화하는 항체 및 그의 사용 방법
CA3089478C (en) Mica/b antibodies and methods of use
RU2815101C2 (ru) Антитела против mica/b, блокирующие шеддинг mica/b, и способы их применения
RU2821021C2 (ru) Антитела к mica/b и способы применения
BR112021001808B1 (pt) Anticorpo monoclonal ou um fragmento de ligação ao antígeno, composição farmacêutica e uso do referido anticorpo monoclonal ou fragmento
TWI790193B (zh) 調控免疫反應之方法及抗體
KR102793781B1 (ko) Hla-g에 특이적으로 결합하는 항체 및 이의 용도
JP2025525073A (ja) エフェクター機能が増強された抗ｍｉｃａ／ｂ抗体および使用方法
TW202336033A (zh) 抗體之新穎組合及用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)